Equillium (Nasdaq: EQ) granted an inducement award of nonstatutory stock options to a new employee under its 2024 Inducement Plan.
The award covers 145,000 shares at an exercise price of $3.08 per share, vesting over four years, and was approved under Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
Key Figures
Current price:$3.08Inducement options:145,000 sharesExercise price:$3.08 per share+5 more
8 metrics
Current price$3.08Closing stock price on June 1, 2026
Inducement options145,000 sharesNonstatutory stock options granted to new employee
Exercise price$3.08 per shareInducement option strike, equal to June 1, 2026 close
Vesting schedule4 years (25% + 36 months)25% after one year, remainder monthly over 36 months
Registered shares18,878,101 sharesCommon stock registered for resale under S-3
Pre-funded warrant shares17,698,593 sharesUnderlying shares of pre-funded warrant in registration
Private placement size$35.0 millionPrivate placement closed March 13, 2026
Warrant exercise price$0.0001 per shareExercise price of pre-funded warrant
Market Reality Check
Price:$3.08Vol:Volume 895,518 is 1.45x t...
normal vol
$3.08Last Close
VolumeVolume 895,518 is 1.45x the 20-day average of 616,547, indicating elevated interest ahead of this routine HR announcement.normal
TechnicalTrading above the $1.61 200-day MA at a price of $3.08, and within 1.28% of the 52-week high $3.12.
Peers on Argus
EQ was up 6.21% while close peers showed mixed moves: BMEA up 1.4%, but CRBP, FA...
EQ was up 6.21% while close peers showed mixed moves: BMEA up 1.4%, but CRBP, FATE, AVTX, and ZURA down between about 0.36% and 1.63%, pointing to stock-specific dynamics rather than a broad biotech move.
Common CatalystAnother peer, FATE, also reported Nasdaq Rule 5635(c)(4) inducement awards, suggesting a shared cadence of routine employment-related equity grants in the space.
Oppenheimer Innovation on the Island presentation and investor meetings.
Pattern Detected
Recent corporate updates, including conferences, investor events, earnings, and prior inducement grants, have generally coincided with positive next-day price reactions.
Recent Company History
Over the last few months, Equillium has combined financing, pipeline planning, and active investor outreach. An earnings update on May 13, 2026 highlighted reduced operating expenses, a $35 million private placement, and cash of $61.3 million expected to fund operations into 2029, which was followed by a 12.12% move. Conference and investor-event announcements on April 20, May 20, and May 28 all saw positive reactions. A prior inducement grant on May 1 also aligned with a modest gain.
Regulatory & Risk Context
Active S-3 Shelf · $35.0 million
Shelf Active
Active S-3 Shelf Registration
2026-04-07
$35.0 millionregistered capacity
An effective S-3 dated April 7, 2026 registers 18,878,101 common shares for resale by a selling stockholder, including 17,698,593 pre-funded warrant shares. The company will receive no proceeds from these resales, while the previously closed $35.0 million private placement and low warrant exercise price of $0.0001 define the economics.
Market Pulse Summary
This announcement details a standard inducement grant of 145,000 nonstatutory stock options at $3.08...
Analysis
This announcement details a standard inducement grant of 145,000 nonstatutory stock options at $3.08 under Equillium’s 2024 Inducement Plan, vesting over four years per Nasdaq Listing Rule 5635(c)(4). In context, the company recently completed a $35.0 million private placement and registered 18,878,101 shares for resale, while also extending its cash runway. Investors may watch future equity grants, insider activity, and pipeline milestones as additional signals.
Key Terms
nasdaq listing rule 5635(c)(4), nonstatutory stock options, form 144, schedule 13g/a, +4 more
8 terms
nasdaq listing rule 5635(c)(4)regulatory
"approved the stock option as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
nonstatutory stock optionsfinancial
"granted an inducement award consisting of nonstatutory stock options to purchase"
A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.
form 144regulatory
"EQ filed a Form 144 reporting proposed sales of Common Stock."
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
schedule 13g/aregulatory
"Equillium, Inc. Schedule 13G/A: ADAR1-related entities and Daniel Schneeberger report"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
rule 10b5-1 trading planregulatory
"The sales were carried out under a pre-arranged Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
pre-funded warrantfinancial
"a pre-funded warrant exercisable for 17,698,593 shares."
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
reverse stock splitfinancial
"approved an amendment allowing a potential reverse stock split of the common stock"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
beneficial ownership limitationregulatory
"prefunded-warrant shares excluded due to a 9.99% beneficial ownership limitation."
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June 1, 2026, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 145,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price per share equal to $3.08, Equillium’s closing stock price on June 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Equillium through the applicable vesting dates. The stock option is subject to the terms and conditions of Equillium’s 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant.
About Equillium Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.
Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; and whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
What inducement stock option grant did Equillium (NASDAQ: EQ) announce on June 2, 2026?
Equillium announced a nonstatutory stock option inducement grant for a new employee covering 145,000 common shares. According to Equillium, the options were granted under its 2024 Inducement Plan as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4).
How many Equillium (EQ) shares are included in the June 2026 inducement stock option award?
The June 2026 inducement stock option award covers 145,000 shares of Equillium common stock. According to Equillium, these options are part of the company’s 2024 Inducement Plan and were granted to a single new employee as an employment incentive.
What is the exercise price of Equillium’s June 1, 2026 inducement stock options for EQ shares?
The inducement stock options have an exercise price of $3.08 per Equillium share. According to Equillium, this price equals the company’s closing stock price on June 1, 2026, the grant date set by the Board’s Compensation Committee.
What is the vesting schedule for Equillium’s 145,000-share inducement stock option grant (EQ)?
The inducement options vest over four years, with 25% vesting after one year and the remainder monthly. According to Equillium, the remaining 75% vests in equal monthly installments over 36 months, subject to the employee’s continued service with the company.
Why did Equillium grant stock options under Nasdaq Listing Rule 5635(c)(4) for EQ?
Equillium used Nasdaq Listing Rule 5635(c)(4) to grant options as a material inducement to employment. According to Equillium, the Compensation Committee approved the award for a new employee specifically under this rule and the company’s 2024 Inducement Plan.
How does Equillium’s 2024 Inducement Plan relate to the June 2026 EQ stock option grant?
The June 2026 stock option grant was issued under Equillium’s 2024 Inducement Plan. According to Equillium, the options are governed by this plan and a related stock option agreement, which define the terms, conditions, and vesting requirements for the inducement award.
